Basilea Pharmaceutica Ltd., of Basel, Switzerland, said, following further discussion with the FDA regarding antibiotic candidate ceftobiprole, the agency confirmed that potential regulatory approval for use in pneumonia in the U.S. would require additional phase III data, specifically prospective data in community-acquired and hospital-acquired pneumonia in accordance with the FDA's new guidelines.